Immuneering (NASDAQ:IMRX) Price Target Raised to $18.00

Immuneering (NASDAQ:IMRX) had its target price raised by Needham & Company LLC from $11.00 to $18.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

IMRX has been the topic of several other reports. Oppenheimer restated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald began coverage on Immuneering in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immuneering currently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

Immuneering Trading Up 0.2%

Immuneering stock opened at $4.47 on Monday. The company has a market cap of $289.21 million, a PE ratio of -3.82 and a beta of 0.41. Immuneering has a 1 year low of $2.90 and a 1 year high of $10.08. The company’s 50-day moving average is $4.78 and its two-hundred day moving average is $5.07.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.09. Research analysts forecast that Immuneering will post -1.09 EPS for the current year.

Institutional Trading of Immuneering

A number of hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Immuneering during the 1st quarter worth approximately $32,000. Geode Capital Management LLC grew its holdings in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares during the period. XTX Topco Ltd bought a new stake in Immuneering in the second quarter valued at approximately $90,000. Bridgeway Capital Management LLC increased its stake in Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in Immuneering in the second quarter worth $215,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.